PLK1 and neoplasm: Similarly, Chen et al. developed LHNPs for efficient co-delivery of CRISPR/Cas9 targeting PLK1, and they found that these LHNPs effectively inhibited tumor growth and improved tumor-bearing mouse survival [92].